Semaglutide

Mechanism of action

Semaglutide is a 31-amino-acid synthetic peptide structurally derived from native human GLP-1 with two engineered modifications that confer dramatic plasma half-life extension and protease resistance. The first modification is substitution of native alanine at position 8 with α-aminoisobutyric acid (Aib), an unnatural amino acid that blocks dipeptidyl peptidase-4 (DPP-4)-mediated cleavage of the N-terminal His-Ala bond — the principal degradation pathway of native GLP-1 (plasma half-life ~2 minutes). The second modification is covalent attachment of a C18 fatty diacid moiety to the ε-amino group of lysine 26 via a γ-glutamic acid and two short polyethylene glycol-like linkers (2xOEG). The fatty diacid chain binds non-covalently but with very high affinity to circulating serum albumin (~67 kDa), shielding the peptide from renal filtration and protease degradation and producing the ~7-day plasma half-life that supports once-weekly subcutaneous dosing. Mechanistically, semaglutide functions as a full GLP-1 receptor agonist with binding affinity comparable to native GLP-1. The GLP-1R is a 463-residue class B G-protein-coupled receptor expressed prominently on pancreatic β-cells (the principal therapeutic target), pancreatic α-cells, intestinal mucosa, central neurons (hypothalamic arcuate nucleus, area postrema), peripheral vagal neurons, vascular smooth muscle, and other tissues. Receptor activation triggers Gαs/adenylate cyclase signalling, raising intracellular cAMP and activating both protein kinase A (PKA) and the Epac2 guanine nucleotide exchange factor. The principal therapeutic effects emerge from receptor activation in distinct tissues. β-cell GLP-1R activation potentiates glucose-stimulated insulin secretion in a strictly glucose-dependent manner — at low glucose concentrations the insulinotropic signal is minimal, which provides the favourable hypoglycaemia profile that distinguishes incretin-based therapy from sulphonylureas. α-cell GLP-1R activation suppresses glucagon secretion, providing a complementary glucose-lowering mechanism. Central GLP-1R activation in the hypothalamic arcuate nucleus and brainstem area postrema drives appetite suppression, early satiety, and reduced food intake — the principal mechanism behind the dramatic weight-loss efficacy seen at higher dose tiers (Wegovy). Peripheral effects include slowed gastric emptying (which flattens the postprandial glucose excursion), modest blood pressure reduction, and emerging neuroprotective effects. The oral semaglutide formulation (Rybelsus) addresses the standard gastric peptide-degradation problem through co-formulation with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), an absorption enhancer that temporarily raises gastric pH and protects semaglutide from peptidase degradation during a narrow gastric absorption window. Oral bioavailability is materially lower than subcutaneous (~1% versus near-complete), but the SNAC platform enables daily oral dosing as an alternative to weekly injection. The licensed daily oral doses (3, 7, 14 mg) achieve plasma exposures comparable to the weekly subcutaneous doses. Downstream metabolic effects of sustained GLP-1R activation produce the characteristic semaglutide phenotype: 1-2% absolute HbA1c reduction in type-2 diabetes, 6-15% body weight reduction (depending on dose and duration), favourable lipid changes, modest blood pressure reduction, and cardiovascular event reduction documented in dedicated outcome trials (SUSTAIN-6, PIONEER, STEP, SELECT). The strictly glucose-dependent insulinotropic profile means severe hypoglycaemia is rare in monotherapy use; risk rises with concurrent sulphonylurea or insulin therapy.

Semaglutide 2.4 mg subcutaneous weekly produces 14.9% mean body weight loss over 68 weeks in non-diabetic adults with obesity (STEP 1, Wilding et al., NEJM 2021) — the largest pharmacological weight-loss effect documented in a peer-reviewed trial at the time of publication, transforming the regulatory and commercial landscape of obesity therapeutics.

— Notable finding

Research history

Semaglutide was developed by Novo Nordisk through systematic medicinal chemistry building on the company's experience with liraglutide, the first commercially successful long-acting GLP-1R agonist (FDA-approved 2010, MHRA-licensed shortly after). The development goal was once-weekly rather than once-daily dosing through extended fatty-acid-acylation chemistry, which became the principal differentiator of semaglutide over liraglutide and exenatide. Phase II development confirmed the once-weekly dosing pharmacology; Phase III SUSTAIN programme (multiple trials across type-2 diabetes settings) established efficacy and safety, supporting first FDA approval (Ozempic, December 2017) and MHRA marketing authorisation shortly after. The SUSTAIN-6 cardiovascular outcome trial (Marso et al., NEJM 2016) — published before regulatory approval — established MACE reduction with semaglutide in type-2 diabetes patients with established cardiovascular disease, paralleling the LEADER trial results for liraglutide. Cardiovascular benefit at the class level (GLP-1R agonists) transformed the regulatory and reimbursement landscape, supporting broader use beyond pure glycaemic control. The weight-management indication emerged from observation that the higher dose tiers used in some Phase III trials produced substantial weight loss beyond the glycaemic control. The STEP programme (multiple Phase III trials, 2018-2021) tested semaglutide 2.4 mg subcutaneous weekly in obesity without diabetes, demonstrating ~15% mean body weight reduction over 68 weeks — substantially larger than any prior pharmacological weight-loss intervention. Wegovy received FDA approval in June 2021 and MHRA marketing authorisation in 2022, generating the explosive 'GLP-1 weight loss' commercial and cultural phenomenon of 2023-2025. UK supply constraints were severe through 2023-2024, partially resolved by 2025-2026. The oral semaglutide formulation (Rybelsus) received FDA approval in September 2019 and MHRA marketing authorisation in 2020 as the first orally bioavailable GLP-1R agonist, enabled by the SNAC absorption-enhancer platform licensed from Emisphere Technologies. The SELECT cardiovascular outcome trial (2023) extended cardiovascular benefit to non-diabetic obese subjects, further broadening the population eligible for chronic GLP-1R agonist therapy. In the UK in 2025-2026, semaglutide is widely prescribed for type-2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), with NICE technology appraisal guidance supporting NHS prescription within specified eligibility criteria. The compound has materially altered the standard-of-care landscape for both conditions.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Semaglutide has the largest published clinical-trial safety dataset of any peptide drug, accumulated through the SUSTAIN, PIONEER, STEP, SELECT, and post-marketing surveillance programmes spanning over 50,000 trial participants and millions of post-marketing exposures. The principal documented adverse events are gastrointestinal: nausea (15-44% depending on dose), vomiting (5-25%), diarrhoea (10-30%), and constipation (15-25%). These are dose-dependent, most prominent during dose escalation, and generally mild-to-moderate; they account for the majority of treatment discontinuations. Dose-titration protocols (starting at 0.25 mg subcutaneous weekly, escalating to therapeutic doses over 16+ weeks) substantially mitigate the GI symptom burden. The glucose-dependent insulinotropic mechanism produces a favourable hypoglycaemia profile in monotherapy. Severe hypoglycaemia is rare when semaglutide is used alone or with metformin; risk rises materially with concurrent sulphonylurea or insulin therapy, where dose reductions of the concurrent agents are recommended. Less common but clinically significant adverse events documented in the published trials include acute pancreatitis (uncommon, with absolute rates of 0.3-0.5% but elevated relative to placebo in some analyses), acute biliary disease (cholecystitis and cholelithiasis, related to rapid weight loss and GLP-1 effects on biliary motility), modest heart rate elevation (~2-5 bpm), injection-site reactions for the subcutaneous formulations, and rare reports of diabetic retinopathy progression in patients with pre-existing severe retinopathy. The theoretical thyroid C-cell carcinoma concern carried forward from earlier GLP-1R agonists (liraglutide, exenatide) — based on rodent thyroid C-cell hyperplasia in chronic toxicity studies — is reflected in the FDA boxed warning and MHRA Summary of Product Characteristics contraindication for personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. The human clinical relevance of the rodent finding remains debated; large epidemiological analyses have not confirmed an increased medullary thyroid carcinoma risk in GLP-1R-agonist-treated patients, but the contraindication is maintained. The SELECT and STEP programmes documented favourable cardiovascular and renal safety profiles, with the SUSTAIN-6 and SELECT trials demonstrating MACE reduction in cardiovascular-risk populations. Mood and suicidality concerns raised in 2023-2024 by isolated case reports have been examined in formal regulatory reviews (FDA, EMA, MHRA) which concluded that the available evidence does not establish a causal association between semaglutide therapy and suicidality, though monitoring continues. Anti-semaglutide antibodies develop in a small proportion of treated patients but are generally non-neutralising and have not produced documented loss of efficacy.

UK regulatory status

Semaglutide is fully MHRA-licensed in the United Kingdom across three formulations and indications. **Ozempic** (semaglutide 0.5, 1.0, 2.0 mg subcutaneous weekly) is licensed for type-2 diabetes mellitus in adults. **Wegovy** (semaglutide 2.4 mg subcutaneous weekly with mandated titration schedule) is licensed for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity. **Rybelsus** (semaglutide 3, 7, 14 mg oral daily) is licensed for type-2 diabetes mellitus in adults as the first orally bioavailable GLP-1R agonist. NHS prescription is supported by NICE technology appraisal guidance (TA875 for Wegovy in obesity, TA664 for Ozempic in type-2 diabetes) within specified eligibility criteria. NHS supply of Wegovy is restricted to specialist obesity services or under shared-care arrangements; private prescription is also available. Ozempic and Rybelsus are routinely prescribed in primary care for type-2 diabetes within NICE-defined treatment pathways. Semaglutide is a Prescription Only Medicine (POM) under the Human Medicines Regulations 2012. Supply or possession for human use outside a valid prescription is regulated. There is no controlled-drug classification under the Misuse of Drugs Act 1971. Unauthorised online supply of unlicensed or counterfeit semaglutide has been a recurring MHRA enforcement concern, particularly during the 2023-2024 supply shortages; the MHRA has published multiple warnings about counterfeit Ozempic and Wegovy entering the UK supply chain through unauthorised channels. WADA does not classify GLP-1R agonists as prohibited; semaglutide is not on the WADA Prohibited List as of 2026. Recreational athletic use raises distinct ethical and safety considerations but is not currently a doping violation.

Frequently asked questions